Literature DB >> 16930546

Prenylated Rab acceptor 1 (PRA1) inhibits TCF/beta-catenin signaling by binding to beta-catenin.

Jong-Tae Kim1, Mi-Young Cho, Seung-Chul Choi, Jung Woo Kim, Suhn-Kee Chae, Do-Young Yoon, Jae Wha Kim, Jong-Seok Lim.   

Abstract

The prenylated Rab acceptor 1 (PRA1) is a ubiquitously expressed 21 kDa protein containing two transmembrane domains that possibly induce its localization to the Golgi complex. It binds to prenylated Rab GTPases and VAMP2. In this study, we report that PRA1-overexpressing cells exhibited a significantly retarded growth rate as compared to that of the mock-transfected cells, and the transcriptional activity of TCF, as evaluated by TOPflash luciferase reporter assay, was profoundly reduced in the PRA1-overexpressed cells. These intracellular functions of PRA1 were verified by introducing deletion mutant or site-directed mutants, or small interfering RNA of PRA1. In addition, the translocation of beta-catenin from the cytosol to the nucleus was blocked to a significant degree in the PRA1-cells, and the interaction of PRA1 and beta-catenin was identified by confocal microscopy and immunoprecipitation analysis. Finally, we observed that the inhibition of TCF/beta-catenin signaling by PRA1 is associated with ERK1/2 dephosphorylation. Therefore, our data suggest that the in vivo modulation of PRA1 may be involved in TCF/beta-catenin signaling, as well as cellular proliferation and tumorigenesis.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16930546     DOI: 10.1016/j.bbrc.2006.08.026

Source DB:  PubMed          Journal:  Biochem Biophys Res Commun        ISSN: 0006-291X            Impact factor:   3.575


  4 in total

1.  Proteome-wide dysregulation by PRA1 depletion delineates a role of PRA1 in lipid transport and cell migration.

Authors:  Hao-Ping Liu; Chih-Ching Wu; Hung-Yi Kao; Yi-Chuan Huang; Ying Liang; Chia-Chun Chen; Jau-Song Yu; Yu-Sun Chang
Journal:  Mol Cell Proteomics       Date:  2010-06-30       Impact factor: 5.911

2.  PRAF2 overexpression predicts poor prognosis and promotes tumorigenesis in esophageal squamous cell carcinoma.

Authors:  Zhaoye Qian; Bin Wei; Yu Zhou; Qiuzi Wang; Jiru Wang; Yuan Sun; Yong Gao; Xiaofei Chen
Journal:  BMC Cancer       Date:  2019-06-14       Impact factor: 4.430

3.  Mutual regulation of JAG2 and PRAF2 promotes migration and invasion of colorectal cancer cells uncoupled from epithelial-mesenchymal transition.

Authors:  Wan He; Jun Tang; Wenwen Li; Yong Li; Yi Mei; Lisheng He; Keli Zhong; Ruilian Xu
Journal:  Cancer Cell Int       Date:  2019-06-11       Impact factor: 5.722

4.  PRAF2 expression indicates unfavorable clinical outcome in hepatocellular carcinoma.

Authors:  Chun-Hua Wang; Li-Li Liu; Ding-Zhun Liao; Mei-Fang Zhang; Jia Fu; Shi-Xun Lu; Shi-Lu Chen; Hong Wang; Shao-Hang Cai; Chris Zhiyi Zhang; Hui-Zhong Zhang; Jing-Ping Yun
Journal:  Cancer Manag Res       Date:  2018-07-25       Impact factor: 3.989

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.